INTERLEUKIN-1??-MEDIATED PROMOTION OF LONG-TERM ALLOENGRAFTMENT AND SHORT-TERM NEUTROPHIL EXPANSION DOES NOT REQUIRE THE PRESENCE OF EITHER DONOR OR HOST T CELLS1
- 1 September 1996
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 62 (5) , 636-642
- https://doi.org/10.1097/00007890-199609150-00017
Abstract
In earlier studies, we showed that a 14-day continuous subcutaneous infusion of recombinant human interleukin (IL)-1 accelerated neutrophil recovery and enhanced long-term chimerism in a bone marrow (BM) transplant model in which T-cell-depleted BALB/c donor BM was given to irradiated C57BL/6 fully allogeneic recipients. We have extended these studies to a model entirely devoid of donor and host T cells. In the model, donor BALB/c congenic severe combined immunodeficient (C.B-17-scid/scid) BM cells are T cell depleted. The cells are then transplanted into adult irradiated C57BL/6 hosts that have been thymectomized and treated with anti-CD4 and CD8. When IL-1 alpha was delivered subcutaneously using a mini-osmotic pump, it enhanced short-term neutrophil recovery and longer term alloengraftment despite the absence of T cells in the donors and the hosts. Therefore, T cells were not required for the promotional effects of IL-1 alpha on neutrophil recovery and alloengraftment. Studies also showed that the potency of the IL-1 alpha effects was related to the degree of donor cell engraftment, which was related to the irradiation dose and the presence of T cells. We conclude that IL-1 alpha can augment post-BM transplantation hematopoietic recovery and alloengraftment via a T-cell-independent mechanism by favoring donor allogeneic hematopoietic progenitor cell competition over limited numbers of host progenitor cells.Keywords
This publication has 40 references indexed in Scilit:
- Interleukin-1 alpha administered after autologous transplantation: a phase I/II clinical trialBlood, 1994
- Cytokine dysregulation and acute graft-versus-host diseaseBlood, 1992
- Promotion of murine marrow alloengraftment and hematopoietic recovery across the major histocompatibility barrier by administration of recombinant human interleukin-1 alpha [see comments]Blood, 1992
- Effect of recombinant human macrophage colony-stimulating factor in irradiated murine recipients of T-cell-depleted allogeneic or non- depleted syngeneic bone marrow transplantsBlood, 1992
- Interleukin-1 and interleukin-1 antagonismBlood, 1991
- Pretreatment of murine donor grafts with L-leucyl-L-leucine methyl ester: elimination of graft-versus-host disease without detrimental effects on engraftmentBlood, 1990
- Interleukin-1 enhances survival of lethally irradiated mice treated with allogeneic bone marrow cellsBlood, 1989
- Improved survival and leukocyte reconstitution without detrimental effects on engraftment in murine recipients of human recombinant granulocyte colony-stimulating factor after transplantation of T-cell- depleted histoincompatible bone marrowBlood, 1989
- Interleukin-1 alpha enhances the in vitro survival of purified murine granulocyte-macrophage progenitor cells in the absence of colony- stimulating factorsBlood, 1988
- Enhanced survival but reduced engraftment in murine recipients of recombinant granulocyte/macrophage colony-stimulating factor following transplantation of T-cell-depleted histoincompatible bone marrowBlood, 1988